Abdominal aortic aneurysm (AAA) is a dangerous swelling of the abdominal aorta, the vascular conduit that supplies oxygenated blood to the legs. Rupture of AAAs account for 15,000 deaths annually in the US. Open surgical repair of AAAs is currently the gold standard therapy, but comes with significant drawbacks: mid-procedure mortality rates range from 1.4-7.6%, and a number of patients are ineligible for the surgery because they cannot tolerate its invasiveness. As an alternative to open surgical repair, many new stent-grafts have been developed that slide into the aorta and essentially exclude the aneurysm from circulation. These devices are seen as a promising treatment that could reduce mortality rates, patient recovery time, and procedural costs, yet current stent-grafts are suboptimal: only about half of AAA patients are eligible for stent-graft treatment because of the varying anatomy of aneurysms, and the stent-grafts themselves suffer from long-term durability issues involving leaking and the migration of the devices from the site of the aneurysm. To address these issues this E-Team proposes to develop a stent-graft with an adhesive delivery platform that actively seals the stent-graft and fixes it securely in place in the aorta.
Update: the team, now incorporated as Endoluminal Sciences, has received $2 million in venture capital funding and is moving toward clinical trials.